¹Ù·Î°¡±â ¸Þ´º

¹Ù·Î°¡±â ¸Þ´º º»¹®³»¿ë ¹Ù·Î°¡±â ¸ÞÀθ޴º ¹Ù·Î°¡±â

ÁÖ¿ä¾È³»

HOME »çÀÌÆ®¸Ê

FONT SIZE

ÆùƮũ±â Å°¿ò 100% 110% 120% 130% 140% ÆùƮũ±â ÁÙÀÓ
¸Þ´ºº¸±â
 
Á¦¸ñ
9/5ÀÏ ¹ßÇ¥ ³í¹®ÀÔ´Ï´Ù.
ÀÛ¼ºÀÏ
2020-09-04
Á¶È¸¼ö
302


¾È³çÇϼ¼¿ä ö±ÕÀÔ´Ï´Ù. 
À̹ø¿¡ Åä¿äÀÏ ¼¼¹Ì³ª¿¡¼­ ¹ßÇ¥ µå¸± ³í¹®Àº
Áö³­´Þ (2020³â 8¿ù) nature¿¡ ¹ßÇ¥µÈ ³í¹®À¸·Î 
Á¦¸ñÀº "cDC1 prime and licensed by CD4+ T cells to induced anti-tumour immunity" ÀÔ´Ï´Ù. 
±âÁ¸¿¡ cDC1Àº CD8+ T cell response¸¦ À¯µµÇϴµ¥ ƯȭµÇ¾î ÀÖ°í, cDC2ÀÇ °æ¿ì CD4+ T cell response¸¦ À¯µµÇϴµ¥ Ưȭ µÇ¾î ÀÖ¾î ÀÖ´Ù°í º¸°í µÇ¾úÀ¸¸ç, tumour protectionÀÇ °üÁ¡¿¡¼­´Â CD4+ T cellÀÇ ¿ªÇÒÀº CD8+ T cell ÀÇ È°¼ºÀ» º¸Á¶ÇÏ´Â °ÍÀ¸·Î ¹Þ¾Æµé¿© Áö°í ÀÖ¾ú½À´Ï´Ù. 

¹°·Ð cDC1ÀÌ CD4+ T cell ¹ÝÀÀÀ» ÀüÇô À¯µµÇÏÁö ¸øÇÏ´Â °ÍÀº ¾Æ´Ï¸ç, ¸î¸î in vitro½ÇÇèÀ» ±â¹ÝÀ¸·Î ÇÑ º¸°í¿¡¼­ CD4+ T cell ¹ÝÀÀ¿¡¼­ÀÇ ¿ªÇÒÀ» °­Á¶Çϱ⵵ Çß½À´Ï´Ù. ÇÏÁö¸¸ in vivo¿¡¼­ÀÇ ¿¬±¸´Â ÀÌ·ç¾î Áø °ÍÀÌ ¾ø¾ú´Âµ¥, 
À̹ø ³í¹®¿¡¼­ cDC1ÀÌ Á÷Á¢ÀûÀ¸·Î CD4+ T cellÀÇ ¹ÝÀÀ¿¡µµ °ü¿©¸¦ Çϸç, ±× ¹ÝÀÀÀÌ tumour-protectionÀÇ °üÁ¡¿¡¼­µµ ¸Å¿ì Áß¿äÇÔÀ» ´Ù¾çÇÑ conditional KO mouse¸¦ ÀÌ¿ëÇÏ¿© in vivo ¼öÁØ¿¡¼­ ¹àÇû½À´Ï´Ù. 

Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù. 
³í¹® ¸µÅ© : https://www.nature.com/articles/s41586-020-2611-3
÷ºÎÆÄÀÏ:
÷ºÎÆÄÀÏÀÌ ¾ø½À´Ï´Ù.
´ÙÀ½±Û
9/12 ¹ßÇ¥ ³í¹®ÀÔ´Ï´Ù.
/ ¼Õ¿ìÁø
¾È³çÇϼ¼¿ä. ¿ìÁøÀÔ´Ï´Ù. Á¦°¡ À̹øÁÖ ¹ßÇ¥ÇÒ ³í¹®Àº 2020 6¿ù Journal of Immunology¿¡ ÃâÆÇµÈ 'Interplay between RAGE and TLR4 Regulates HMGB1-Induced Inflammation by Promoting Cell Surface Expression of RAGE and TLR4' ÀÔ´Ï´Ù. Systemic inflammtion »óȲ¿¡¼­ hepatocyte¿¡ ÀÇÇÑ HMGB1 ºÐºñ°¡ leth..
ÀÌÀü±Û
9/5 ¹ßÇ¥³í¹®ÀÔ´Ï´Ù.
/ ±è³ª·¡
¾È³çÇϼ¼¿ä ³ª·¡ÀÔ´Ï´Ù. ¹ßÇ¥³í¹® ¼±Á¤ÇÏ¿© º¸³»µå¸³´Ï´Ù. Á¦°¡ À̹øÁÖ ¹ßÇ¥ÇÏ°Ô µÉ ³í¹®Àº ¿ÃÇØ 5¿ù PLOS PATHOGEN(IF:6.463)¿¡ °ÔÀçµÈ ³í¹®À¸·Î PRRSV infection »óȲ¿¡¼­ PRRSVÀÇ Nsp2¿¡ ÀÇÇØ activationµÈ TREM2¶ó´Â moleculeÀÌ pro-inflammatory response¸¦ ¾ïÁ¦½ÃÄÑ PRRSVÀÇ °¨¿°À» ÃËÁø½ÃŲ´Ù´Â ³»¿ëÀÇ ³í¹®À¸..